2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Hall B
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Monoclonal Antibody Therapy, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

245 A phase 2 trial investigating decitabine in combination with a JAK-inhibitor as a bridge to allogeneic hematopoietic cell transplant in patients with accelerated and blast phase myeloproliferative neoplasms

Anna Halpern, MD, Othus Megan, PhD2, Jacob Appelbaum, MD/PhD3, Kimberly Cadiz4, Noah Pinke5, Eva Gill6, Kathryn (Katie) D. Russell, ARNP7, Chiara Perni, BA8, Mary-Elizabeth Percival, MD9, Paul Hendrie, MD, PHD10, Cristina Maria Ghiuzeli, MD11, Vivian Oehler, MD12, Rachel B Salit, MD13, Joachim Deeg, MD14, Bart L Scott, MD15
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 University of Washington, Seattle, Washington, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 University of Washington, Seattle, Washington, United States
8 University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 University of Washington, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction: Myeloproliferative neoplasms in accelerated or blast phase (MPN-AP/BP) have a poor prognosis, with a median overall survival (OS) of 3–6 months without allogeneic cell transplant (HCT). HCT is the only curative option, but only 10–20% of patients undergo HCT due to age, comorbidities, or rapid clinical deterioration. Even after HCT, 1-year OS is only 40%. Further, there is no standard pre-HCT management approach. Cytoreduction appears warranted as reducing disease burden before transplant is associated with improved OS. Historic options have included intensive chemotherapy, which may be effective in blast reduction but confers excessive toxicity, or hypomethylating agents (HMA) which are better tolerated but have low complete remission (CR) rates. The JAK1/2 inhibitor (JAKi) ruxolitinib is known to reduce symptom burden and prolong survival in myelofibrosis (MF) patients and also improves post-HCT outcomes We therefore evaluated the effectiveness of 10-day decitabine combined with JAK inhibition in patients with MPN-AP/BP before HCT (clinicaltrials.gov: NCT04282187).   

Methods: Eligible patients were age ≥18 years with MPN (2016 WHO Criteria: MF, PV, ET, MPN-unclassifiable, MDS/MDS) and ≥5% myeloblasts in bone marrow and/or peripheral blood. Other requirements included: ECOG performance status 0-2, adequate organ function (creatinine clearance ≥50 ml/min, bilirubin ≤3, AST/ALT <3 x ULN) and critically, be considered a HCT candidate with a plan to proceed to allogeneic HCT (donor identification not required). Prior chemotherapy was exclusionary. Treatment consisted of decitabine 20 mg/m2/day IV Days 1-10 of a 28-day cycle and a physician-selected JAKi (ruxolitinib, fedratinib, or pacritinib) given orally continuously. JAKi dosing followed standard of care based on blood counts and concomitant medications.  Up to 6 cycles of Decitabine+JAKi before HCT were allowed. Responses were assessed by clinical and bone marrow criteria (post-MPN AML Consortium Criteria) after cycles 2, 4, and 6. Once a donor was identified, patients could proceed to HCT at any time.  They continued ruxolitinib through HCT via a separate protocol (NCT04384692). Patients not proceeding to HCT after 6 cycles were removed from study. The primary endpoint was HCT rate. Secondary endpoints included: time to HCT, remission at day 100 post-HCT, 1 year survival post-HCT, response rate, OS, and longitudinal mutational landscape. 

Results: Twenty patients enrolled from 5/2020-1/2026, median age of 64 (range 42-72) years, 15 (75%) male. Underlying MPN was MF in 10, ET in 7, MDS/MPN in 2 and MPN-U in 1; 85% had prior treatment for their MPN, most commonly hydroxyurea. Driver mutations were JAK2 in 6, CALR in 6, and MPL in 2; 17 (85%) of patients had high risk mutations based on the MIPSS70+ v2.0, including 50% with TP53 mutations. Baseline median (range) white blood cell count was 13.1 (2.7-43.4), LDH 594 (187-2092) IU/L and blood/marrow blasts 20% (5-43). Patients received a median of 3 (1-5) cycles of therapy on protocol; the JAKi was ruxolitinib in 14, fedratinib in 4 and pacritinib in 2. 

Thirteen (65%) patients received HCT after a median of 160 (109-273) days from therapy initiation. Reasons for not receiving HCT were death (2), infection (2), disease progression (2), and no caregiver (1). Eleven of the 13 transplanted patients (85%) were alive 100 days post HCT (9 in ongoing CR) with a 77% 1-year post-HCT survival. Responses were: acute leukemia CR in 2, acute leukemia partial response in 5, stable disease in 9, progressive disease in 3, and not evaluable in 1. The combination was well tolerated, however all patients receiving ruxolitinib or fedratinib required JAKi dose reduction for thrombocytopenia due to decitabine or disease. Five patients received additional post protocol therapy prior to HCT, mostly induction-type therapy. 

Median OS for the whole cohort was 24.4 months (95% CI 13.2-not reached). Median OS for HCT patients has not been reached; survival was 57% at 24.5 months (95% CI 35-94%). 

Conclusions: In this very high-risk MPN-AP/BP population, the use of Decitabine+JAKi prior to HCT yielded higher HCT rates and improved 1-year and median OS compared to reported historical rates. Accrual is ongoing. To further validate these findings and mitigate the required JAKi dose reduction for myelosuppression when combined with an HMA, a follow-up study is underway evaluating HMA+pacritinib in this population before HCT (NCT07148947).

Anna Halpern, MD: Merck - Ended employment in the past 24 months; PharmaEssentia - Research Funding; Incyte - Research Funding; Sobi - Research Funding; Merck - Research Funding; Chordia - Research Funding; Jazz - Research Funding; Karyopharm - Research Funding; Disc Medicine - Research Funding; Sumitomo - Research Funding; Protagonist - Research Funding; Sobi - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony)